截至6月3日收盘，毛发医疗概念上涨3.51%，位居概念板块涨幅第5，板块内，19股上涨，朗姿股份、 九芝堂等涨停，水羊股份、百诚医药、泰恩康等涨幅居前，分别上涨12.74%、7.06%、6.52%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 同花顺果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 | 3.08 | 一体化压铸 | -0.21 | | 眼科医疗 | 3.08 | 硅能源 | -0.18 | 资金面上看，今日毛发医疗概念板 ...

Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]

Group 1: Company Overview and Operations - Baicheng Pharmaceutical has an international marketing department responsible for the export sales of active pharmaceutical ingredients and formulations [3] - The company is actively pursuing internationalization, with three active pharmaceutical ingredients (Minoxidil, Amorolfine, and Acetylcysteine) having submitted EU registration applications in 2024 [5] Group 2: Research and Development - In 2024, the company invested CNY 320 million in R&D, with plans to continue expanding R&D efforts [5] - The company has made significant progress in innovative drug development, having obtained two IND approvals for Class 1 new drugs and completed 11 IND submissions for Class 2 new drugs [6] - The company has 98 R&D projects with sales rights as of the end of 2024, of which 25 projects have been approved [6][7] Group 3: Financial Performance - The company reported a net loss of CNY 52,742,809.58 for the year 2024 [6] - Commercial production revenue for 2024 was CNY 36 million, attributed to the subsidiary, Saimer Pharmaceutical [6] Group 4: Strategic Focus - The company aims to balance R&D investment with short-term profitability by enhancing research efficiency and quality [4] - Future growth drivers include expanding the generic drug business, increasing innovative drug initiatives, and enhancing overseas market presence [6]

证券代码：301096 证券简称：百诚医药 公告编号：2025-028 杭州百诚医药科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、 本次股东大会不存在否决议案的情形。 2、 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、 召开时间： （1）现场会议召开时间：2025 年 5 月 14 日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 14 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为 2025 年 5 月 14 日 9:15-15:00 期间的任意时间。 2、 召开地点：浙江省杭州市临平区临平街道绿洲路 159 号 3、 召开方式：现场投票与网络投票相结合的方式 4、 召集人：董事会 5、 主持人：董事长、总经理楼金芳女士 6、 本次会议的召集、 ...

北京海润天睿律师事务所 关 于 杭州百诚医药科技股份有限公司 2024 年年度股东大会的 法律意见书 二○二五年五月 北京市朝阳区建外大街甲 14 号广播大厦 5/9/10/13/17 层 关于本法律意见书，本所及本所律师谨作如下声明： 1、在本法律意见书中，本所及本所律师仅就本次股东大会的召集及召开程序、 出席会议人员及召集人的资格、表决方式、表决程序及表决结果进行核查和见证 并发表法律意见，不对本次股东大会的议案内容及其所涉及的事实和数据的完整 性、真实性和准确性发表意见。 2、本所及本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定以及本 法律意见书出具日以前已经发生的或者存在的事实，严格履行了法定职责，遵循 了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定 的事实真实、准确、完整，所发表的结论性意见合法、准确，不存法律意见书在 虚假记载、误导性陈述或者重大遗漏，并对此承担相应法律责任。 北京市朝阳区建外大街甲 14 号广播大厦 5/9/10/13/17 层 北京海润天睿律师事务所 关于杭州百诚医药科技股份 ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Group 1 - The company's revenue from its generic drug business decreased to 802 million yuan in 2024, a year-on-year decline of 21.18%, with a net profit attributable to shareholders of -53 million yuan, down 119.39% [1] - In Q1 2025, the company reported revenue of 129 million yuan, with a net profit attributable to shareholders of -26 million yuan [1] - Revenue breakdown for 2024 includes: preclinical pharmaceutical research income of 194 million yuan (-42.8%), clinical services income of 213 million yuan (+10.5%), self-developed results transformation income of 288 million yuan (-26.7%), equity sharing income of 8 million yuan (-71.3%), and commercial production income of 37 million yuan [1] Group 2 - As of the end of 2024, the company has nearly 300 self-developed projects that have been established but not yet transformed, with 91 projects completed in the small trial stage, 53 in the pilot scale-up stage, and 78 in the verification production stage [2] - The company has achieved 58 technology transformations of research results in 2024, with over 200 personnel in the new drug research and development team [2] - The company emphasizes its integrated drug development capabilities, combining pharmaceutical research, clinical trials, and customized R&D production, along with a comprehensive production service from intermediates to active pharmaceutical ingredients to formulations [2] Group 3 - The company forecasts revenues for 2025-2027 to be 704 million yuan, 778 million yuan, and 875 million yuan, representing year-on-year changes of -12.2%, +10.6%, and +12.4% respectively [3] - The net profit attributable to shareholders is projected to be 55 million yuan, 103 million yuan, and 119 million yuan for 2025-2027, with year-on-year growth rates of 204.4%, 87.9%, and 15.0% respectively [3] - The company anticipates short-term performance uncertainty due to policy impacts but expects to turn a profit by 2025, leading to a revised "accumulate" rating [3]

| 项目 | 内容 | | --- | --- | | 保荐机构名称 | 国金证券股份有限公司 | | 注册地址 | 成都市青羊区东城根上街 号 95 | | 法定代表人 | 冉云 | | 保荐代表人 | 余波、耿旭东 | | 联系电话 | 021-68826801 | 二、上市公司基本情况 国金证券股份有限公司 关于杭州百诚医药科技股份有限公司首次公开发行股票 并在创业板上市之持续督导保荐总结报告书 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为杭州 百诚医药科技股份有限公司（以下简称"百诚医药"、"公司"或"发行人"）首 次公开发行股票并在创业板上市的保荐机构，负责百诚医药上市后的持续督导工 作，持续督导期至 2024 年 12 月 31 日止。截至目前首次公开发行股票并在创业 板上市的持续督导期限己满，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，保荐机构出具本保荐总结报告书。 一、保荐机构基本情况 | 项目 | 内容 | | --- | --- | | 上市公司名称 | 杭州百诚医药 ...

Core Viewpoint - The company Baicheng Pharmaceutical (301096.SZ) reported a significant decline in revenue and net profit for the year 2024 and the first quarter of 2025, indicating financial distress and operational challenges [2][3][4]. Financial Performance Summary - In 2024, the company achieved operating revenue of 802 million yuan, a decrease of 21.18% compared to 2023 [2][3]. - The net profit attributable to shareholders was -52.74 million yuan, a decline of 119.39% from the previous year's profit of 271.97 million yuan [2][3]. - The net profit after deducting non-recurring gains and losses was -72.63 million yuan, down 128.07% from 258.79 million yuan in 2023 [2][3]. - The net cash flow from operating activities was -195.86 million yuan, compared to a positive cash flow of 90.45 million yuan in the previous year, marking a 316.53% decrease [2][3]. Q1 2025 Performance Summary - For the first quarter of 2025, the company reported operating revenue of 129 million yuan, a decline of 40.32% year-on-year [4]. - The net profit attributable to shareholders was -26.20 million yuan, a decrease of 152.59% from the previous year's profit of 49.82 million yuan [4]. - The net profit after deducting non-recurring gains and losses was -36.18 million yuan, down 174.26% from 48.72 million yuan in the same period last year [4]. - The net cash flow from operating activities was -70.03 million yuan, an improvement of 42.59% compared to -121.98 million yuan in the previous year [4]. Stock Market Performance - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial price of 79.60 yuan per share [5]. - The stock reached a high of 120 yuan on its first trading day but has since experienced a downward trend, currently trading below its initial offering price [4][5]. Fundraising and Use of Proceeds - The company issued 27.04 million shares, raising a total of 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [5][6]. - The final net fundraising amount exceeded the original plan by 1.213 billion yuan, with the funds intended for the headquarters and R&D center project in Hangzhou [5].

杭州百诚医药科技股份有限公司于近日发布2024年年报，数据显示公司多项关键指标出现较大变化，其 中净利润同比下降119.39%，经营活动产生的现金流量净额同比下降316.53%，引发市场关注。 营收净利双降，经营挑战凸显 营业收入下滑21.18% 2024年，百诚医药实现营业收入801,923,244.22元，相较于2023年的1,017,448,123.50元，下降了 21.18%。公司表示，仿制药业务受集采、MAH制度等政策影响，是营业收入下降的主要原因。从业务 板块来看，CRO行业收入为723,506,464.88元，占比90.22%，但同比下降25.02%；CDMO行业收入 41,722,766.77元，占比5.20%，同比下降20.52%；商业化生产收入36,694,012.57元，占比4.58% ，为新增 业务板块。 净利润由盈转亏，降幅达119.39% 归属于上市公司股东的净利润为 -52,742,809.58元，而2023年为271,966,149.52元，同比下降119.39%。 扣除非经常性损益后的净利润为 -72,631,801.94元，203年为258,785,182.11元，同比下降 ...